Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VUSION | — | 2006-02-16 | fda.gov ↗ |
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03561376 | Sep 2021 → Sep 2027 expected | — | Melissa Pugliano-Mauro | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07475364 | May → Dec 2026 expected | dental pulp necrosis | University of Faisalabad | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03650036 | Jun 2018 → May 2019 | dental pulp necrosis | Federal University of Piaui | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03702374 | Sep 2018 → Nov 2020 | diabetic retinopathy | University of Guadalajara | Completed | No outcome recorded |
| Phase 3 | NCT01001975 | Jul → Aug 2009 | skin sensitivity to sun | Bayer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07565181 | Jun 2025 → Jan 2026 | aphthous stomatitis | Faculty of Dental Medicine for Girls | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06158451 | Mar → Aug 2024 | periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| — | NCT05865431 | Mar 2017 → Feb 2018 | hyperpigmentation of the skin | University of California, Davis | Completed | No outcome recorded |
| — | NCT02299206 | Dec 2014 → Jul 2016 | infantile miliaria | Northwestern University | Terminated | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1/2 | NCT02301052 Comparator | Sep → Nov 2014 | hemorrhoid | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04071977 Comparator | Mar 2020 → Oct 2021 | diabetes mellitus, diabetic retinopathy | University of Guadalajara | Completed | No outcome recorded |
| Phase 4 | NCT07193849 Comparator | Dec 2023 → Dec 2025 overdue | decubitus ulcer | King Abdullah Medical City | Recruiting | No outcome recorded |
| Phase 4 | NCT02716415 Comparator | Mar 2015 → Mar 2018 | dermatitis | University of the Philippines | Completed | No outcome recorded |
| Phase 4 | NCT02620345 Background | Jan 2010 → Oct 2015 | benign neoplasm of corpus uteri | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| — | NCT06221046 Comparator | Aug 2026 → Apr 2027 expected | irritant dermatitis | Scotiaderm | Not yet recruiting | No outcome recorded |
| — | NCT07633808 Comparator | Jun → Dec 2026 expected | dermatitis | University of Malaya | Not yet recruiting | No outcome recorded |
| — | NCT07637695 Comparator | Jan → Nov 2023 | irritant dermatitis | Taoyuan Armed Forces General Hospital | Completed | No outcome recorded |
| — | NCT07186907 Comparator | Nov 2017 → Mar 2018 | dermatitis | Gozde AKSUCU | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zinc oxide | “It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗17“Placement of CTZ antibiotic paste (chloramphenicol, tetracycline, zinc oxide mixed with eugenol) in the pulp chamber after irrigation with 3% sodium hypochlorite, followed by...” NCT07475364 ↗ “CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with...” NCT03650036 ↗ “Zinc Oxide Ointment preparations including Calmoseptine Ointment and Desitin Maximum Strength 40% Diaper Rash Paste have been used to treat diaper dermatitis for many years...” NCT02716415 ↗ “Commercially available zinc oxide-based barrier cream will be applied topically to the affected diaper area according to the study protocol and routine clinical practice.” NCT07633808 ↗ “This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w).” NCT02301052 ↗ “CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g)” NCT02299206 ↗ “Patients in the control arm will be treated with a standard zinc oxide barrier cream.” NCT06221046 ↗ “Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole” NCT01001975 ↗ “Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day” NCT02620345 ↗ “zinc (zinc oxide 20 mg)” NCT04071977 ↗ |
| Known as | zinc | “It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide...” NCT03702374 ↗1“zinc (zinc oxide 20 mg)” NCT04071977 ↗ |
| Route | Topical | “application of the trial ointment” NCT02716415 ↗ |